Lee Pharmaceuticals (LPHM) 0.0041 $LPHM
2015 Investigation Report on China's Insulin Lispro Market 2010-2019 Featuring Eli Lilly and Company & Gan & Lee Pharmaceuticals
PR Newswire Europe - Thu Aug 06, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/963t94/investigation [http://www.researchandmarkets.com/research/963t94/investigation]) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2010-2019" [http://www.researchandmarkets.com/research/963t94/investigation] report to their offering.
LLY: 81.80 (+0.96)
Research and Markets: Investigation Report on China's Insulin Lispro Market, 2010-2019 Featuring Eli Lilly and Company & Gan & Lee Pharmaceuticals
Business Wire - Thu Aug 06, 5:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l8n6ks/investigation) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2010-2019" report to their offering.
LLY: 81.80 (+0.96)
Investigation Report on China's Insulin Lispro Market, 2010-2019 Featuring Eli Lilly and Company & Gan & Lee Pharmaceuticals
M2 - Thu Aug 06, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8pbxrk/investigation) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2010-2019" report to their offering. According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development. There are about 90 million diabetes patients in today's China and 95% of them suffer from type 2 diabetes mellitus. And the number of potential patients might reach up to 200 million. For patients with type 1 diabetes mellitus, insulin is the only drug available. Besides, 30%-40% of type 2 diabetes will finally become insulin-dependent. Currently, the diabetic drug market at home and abroad both show rapid growth. Although international giants take up a large share, domestic enterprises are expected to break through in certain fields. The vast number of patients and demand for treatment will drive the diabetic drug market to expand. In recent years, insulin's share in the diabetic drug market has increasingly risen, 42% in the global market while nearly 40% in China. Insulin lispro is a fast-acting insulin analogue. Insulin lispro has one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, avoiding episodes of hypoglycemia. In the late 1990s, insulin lispro made by Eli Lilly and Company entered China. Later insulin lispro made by Gan & Lee Pharmaceuticals also came into the market. After entering China, insulin lispro develops fast with annual sales rising from less than CNY 7 million in 2005 to CNY 142 million in 2014 and CAGR during 2005-2014 reaching up to 40.1%. Currently, insulin lispro in the Chinese market mainly come from Eli Lilly and Company and Gan & Lee Pharmaceuticals. According to this market survey, Eli Lilly and Company has a larger market share of over 99% in 2014 by sales value. Key Topics Covered: 1Related Concepts of Insulin Lispro 2 Market Profile of Insulin Lispro in China 3 Survey on Sales Value of Insulin Lispro in China, 2010-2014 4 Survey on Sales Volume of Insulin Lispro in China, 2010-2014 5 Survey on Market Share of Major Manufacturers of Insulin Lispro in China, 2010-2014 6 Survey on Market Share of Dosage Forms of Insulin Lispro in China, 2010-2014 7 Reference Price of Insulin Lispro in Chinese Hospitals in 2014 8 Major Manufacturers of Insulin Lispro in Chinese Market, 2010-2014 9 Market Outlook of Insulin Lispro in China, 2014-2018 Companies Mentioned - Eli Lilly and Company - Gan & Lee Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/8p...estigation
LLY: 81.80 (+0.96)
The Incidence of Diabetes inside China keeps Growing and the Market Size of Diabetes Drugs Has Expanded Each Year, Exceeding CNY 20 Billion in 2014
M2 - Thu Jun 11, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/62kjcv/investigation) has announced the addition of the "Investigation Report on China's Insulin Glargine Market, 2010-2019" report to their offering. According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while in America it will reach 29.7 million. The fast growth rate of diabetes in China and other developing countries has put a heavy burden on their social and economic development. In China, the third generation of insulin is still in promotion period. Since its price is relatively high, it is mainly used in big cities. The second generation and the third generation of insulin will take the shape of stagger competition. According to the author's survey on some sample hospitals in China, the CAGR of insulin glargine in sample hospitals in China has exceeded 60% during the period of 2014- 2015. Currently, the Chinese market is dominated mainly by Aventis Behring Gmbh (the trade name of insulin glargine is Lantus and the sales in 2014 exceeded USD 7 billion) and the generic drugs (the trade name of insulin glargine is Basalin) made by Gan & Lee Pharmaceutical. As the patent of Lantus expired in February 2015, the global market structure is estimated to change in the next few years. On September 9th 2014, Eli Lilly and Company and Boehringer- ingelheim issued a joint statement that the insulin biosimilar - insulin glargine owned by them has been approved to come into market by the EU. On the other hand, in the Chinese market, some local enterprises are also hastening the development of Lantus's generic drug. Companies Mentioned: - Gan & Lee Pharmaceuticals - Aventis Behring GmbH - Tonghua Dongbao Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/62...estigation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
LLY: 81.80 (+0.96)
2015 Investigation Report on China's Insulin Lispro Market 2010-2019 Featuring Eli Lilly and Company & Gan & Lee Pharmaceuticals
PR Newswire Europe - Thu Aug 06, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/963t94/investigation [http://www.researchandmarkets.com/research/963t94/investigation]) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2010-2019" [http://www.researchandmarkets.com/research/963t94/investigation] report to their offering.
LLY: 81.80 (+0.96)
Research and Markets: Investigation Report on China's Insulin Lispro Market, 2010-2019 Featuring Eli Lilly and Company & Gan & Lee Pharmaceuticals
Business Wire - Thu Aug 06, 5:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l8n6ks/investigation) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2010-2019" report to their offering.
LLY: 81.80 (+0.96)
Investigation Report on China's Insulin Lispro Market, 2010-2019 Featuring Eli Lilly and Company & Gan & Lee Pharmaceuticals
M2 - Thu Aug 06, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8pbxrk/investigation) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2010-2019" report to their offering. According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development. There are about 90 million diabetes patients in today's China and 95% of them suffer from type 2 diabetes mellitus. And the number of potential patients might reach up to 200 million. For patients with type 1 diabetes mellitus, insulin is the only drug available. Besides, 30%-40% of type 2 diabetes will finally become insulin-dependent. Currently, the diabetic drug market at home and abroad both show rapid growth. Although international giants take up a large share, domestic enterprises are expected to break through in certain fields. The vast number of patients and demand for treatment will drive the diabetic drug market to expand. In recent years, insulin's share in the diabetic drug market has increasingly risen, 42% in the global market while nearly 40% in China. Insulin lispro is a fast-acting insulin analogue. Insulin lispro has one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, avoiding episodes of hypoglycemia. In the late 1990s, insulin lispro made by Eli Lilly and Company entered China. Later insulin lispro made by Gan & Lee Pharmaceuticals also came into the market. After entering China, insulin lispro develops fast with annual sales rising from less than CNY 7 million in 2005 to CNY 142 million in 2014 and CAGR during 2005-2014 reaching up to 40.1%. Currently, insulin lispro in the Chinese market mainly come from Eli Lilly and Company and Gan & Lee Pharmaceuticals. According to this market survey, Eli Lilly and Company has a larger market share of over 99% in 2014 by sales value. Key Topics Covered: 1Related Concepts of Insulin Lispro 2 Market Profile of Insulin Lispro in China 3 Survey on Sales Value of Insulin Lispro in China, 2010-2014 4 Survey on Sales Volume of Insulin Lispro in China, 2010-2014 5 Survey on Market Share of Major Manufacturers of Insulin Lispro in China, 2010-2014 6 Survey on Market Share of Dosage Forms of Insulin Lispro in China, 2010-2014 7 Reference Price of Insulin Lispro in Chinese Hospitals in 2014 8 Major Manufacturers of Insulin Lispro in Chinese Market, 2010-2014 9 Market Outlook of Insulin Lispro in China, 2014-2018 Companies Mentioned - Eli Lilly and Company - Gan & Lee Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/8p...estigation
LLY: 81.80 (+0.96)
The Incidence of Diabetes inside China keeps Growing and the Market Size of Diabetes Drugs Has Expanded Each Year, Exceeding CNY 20 Billion in 2014
M2 - Thu Jun 11, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/62kjcv/investigation) has announced the addition of the "Investigation Report on China's Insulin Glargine Market, 2010-2019" report to their offering. According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while in America it will reach 29.7 million. The fast growth rate of diabetes in China and other developing countries has put a heavy burden on their social and economic development. In China, the third generation of insulin is still in promotion period. Since its price is relatively high, it is mainly used in big cities. The second generation and the third generation of insulin will take the shape of stagger competition. According to the author's survey on some sample hospitals in China, the CAGR of insulin glargine in sample hospitals in China has exceeded 60% during the period of 2014- 2015. Currently, the Chinese market is dominated mainly by Aventis Behring Gmbh (the trade name of insulin glargine is Lantus and the sales in 2014 exceeded USD 7 billion) and the generic drugs (the trade name of insulin glargine is Basalin) made by Gan & Lee Pharmaceutical. As the patent of Lantus expired in February 2015, the global market structure is estimated to change in the next few years. On September 9th 2014, Eli Lilly and Company and Boehringer- ingelheim issued a joint statement that the insulin biosimilar - insulin glargine owned by them has been approved to come into market by the EU. On the other hand, in the Chinese market, some local enterprises are also hastening the development of Lantus's generic drug. Companies Mentioned: - Gan & Lee Pharmaceuticals - Aventis Behring GmbH - Tonghua Dongbao Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/62...estigation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
LLY: 81.80 (+0.96)
